Vevorisertib trihydrochloride

Synonyms: ARQ 751 trihydrochloride
Vevorisertib (ARQ 751) trihydrochloride 是一种选择性、变构的 pan-AKT 及 AKT1-E17K 突变抑制剂,可有效抑制 AKT 磷酸化,其对 AKT1 和 AKT1-E17K 的 Kd 值分别为 1.2 nM 和 8.6 nM,对 AKT1、AKT2 和 AKT3 的 IC50 值分别为 0.55、0.81 和 1.3 nM,可用于癌症研究。
产品编号: MS-B99219 纯度: 99.13% CAS No.: 1416775-08-0 分子式: C35H41Cl3N8O 分子量: 696.11
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Vevorisertib (ARQ 751) trihydrochloride 是一种选择性、变构的 pan-AKT 及 AKT1-E17K 突变抑制剂,可有效抑制 AKT 磷酸化,其对 AKT1 和 AKT1-E17K 的 Kd 值分别为 1.2 nM 和 8.6 nM,对 AKT1、AKT2 和 AKT3 的 IC50 值分别为 0.55、0.81 和 1.3 nM,可用于癌症研究。

生物实验数据

生物活性 Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric inhibitor of pan-AKT and the AKT1-E17K mutant that effectively inhibits AKT phosphorylation, with Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively, and IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively, and can be used for cancer research.
IC50 & Target Akt2:0.81 nM, Akt1 (E17K):8.6 nM (Kd), Akt1:1.2 nM (Kd), Akt1:0.55 nM, Akt3:1.31 nM
体外研究
(In Vitro)

Vevorisertib trihydrochloride (0, 12, 33, 111, 333, 1000 nM, 2 hours) inhibits phosphorylation of AKT1-E17K.
Vevorisertib trihydrochloride (1 μM for 2 hours; NIH 3T3 cells are transfected with either pcDNAAKT-WT-GFP or pcDNA-E17K-GFP) inhibits plasma membrane translocation of AKT-WT and AKT1-E17K irrespective of the presence of growth factors.
Vevorisertib trihydrochloride (5 μM) exhibites 57% inhibition of full-length AKT1.
Vevorisertib trihydrochloride (0, 0.012, 0.037, 0.11, 0.33, 1 μM; 2 hours) shows a dose-dependent effect on mTORC1 and AKT direct substrates including PRAS40, GSK3β, FOXO, BAD, and AS160 in cancer cell lines.
Vevorisertib trihydrochloride has anti-proliferative effect on esophageal, breast, and head and neck cancer cells (GI50 < 1 μM).
Vevorisertib trihydrochloride exhibits strong anti-proliferative activity in PIK3CA mutant cell lines.
Vevorisertib trihydrochloride (MK-4440)/imatinib mesylate (IM) combination shows cell cycle arrest, and increases cell death of gastrointestinal stromal tumor (GIST) cells.
Vevorisertib trihydrochloride exhibits strong anti-proliferative activity in PIK3CA mutant cell lines:

Breast Cancer Cell Lines GI50 (nM) PIK3CA ER PR HER2
T47D 1.05 H1047R + + -
EFM-19 1.54 H1047R + + -
MCF-7 2.20 E545K + + -
BT474 3.25 K111N + + +
MDA-MB-453 6.05 H1047R - - +

Western Blot Analysis

Cell Line: 293T cells (transiently transfected with pcDNA-E17K-GFP)
Concentration: 0, 12, 33, 111, 333, 1000 nM
Incubation Time: 2 hours
Result: Inhibited phosphorylation of AKT1-E17K.

Western Blot Analysis

Cell Line: Cancer cell lines: MDA-MB 453 (PIK3CAH1047R; Her2 amp), NCI-H1650 (PTEN null), KU-19-19 (AKT1-E17K&E49K; NRas Q61R)
Concentration: 0, 0.012, 0.037, 0.11, 0.33, 1 μM
Incubation Time: 2 hours
Result: Showed a dose-dependent effect on mTORC1 and AKT direct substrates including PRAS40, GSK3β, FOXO, BAD, and AS160.
体内研究
(In Vivo)

Vevorisertib trihydrochloride (25, 50 and 75 mg/kg; p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days) shows potent tumor growth inhibition of 68, 78 and 98%, respectively.
Vevorisertib trihydrochloride (5, 10, 20, 40, 80, and 120 mg/kg; p.o. daily for ten days) shows tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively.
Vevorisertib trihydrochloride reachs Cmax plasma concentrations of ≥2 μM.
Vevorisertib trihydrochloride is generally well-tolerated at dose levels up to 120 mg/kg.
Vevorisertib trihydrochloride (MK-4440)/IM combination shows superior efficacy in an IM-sensitive preclinical model of GIST compared with either single agent.

Animal Model: Endometrial PDX mouse xenograft models (AKT1-E17K mutation tumor fragments subcutaneously implanted in athymic nude mice; tumor volume of approximately 200 mm3)
Dosage: 25, 50 and 75 mg/kg
Administration: p.o.; 5 days dosing followed by a 4 day dosing holiday for 20 days
Result: Showed potent tumor growth inhibition of 68, 78 and 98%, respectively.
Animal Model: AN3CA mouse xenograft models (female NCr nu/nu mice with 250 mm3 tumors size)
Dosage: 5, 10, 20, 40, 80, and 120 mg/kg
Administration: p.o.; daily for ten days
Result: Showed tumor growth inhibition of 29, 33, 50, 73, 83, and 92%, respectively.
性状 固体
颜色 White to yellow

化学信息

分子量 696.11
分子式 C35H41Cl3N8O
CAS No. 1416775-08-0
别名 ARQ 751 trihydrochloride

储存&溶解度

体内实验配方
10% DMSO+90% Saline: 10 mg/mL (14.37 mM), Solution.
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (7.18 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 150 mg/mL (215.48 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

H2O 中的溶解度 : 25 mg/mL (35.91 mM; 超声助溶 (<60°C))

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O / DMSO1 mM1.4366 mL7.1828 mL14.3655 mL35.9139 mL
5 mM0.2873 mL1.4366 mL2.8731 mL7.1828 mL
10 mM0.1437 mL0.7183 mL1.4366 mL3.5914 mL
15 mM0.0958 mL0.4789 mL0.9577 mL2.3943 mL
20 mM0.0718 mL0.3591 mL0.7183 mL1.7957 mL
25 mM0.0575 mL0.2873 mL0.5746 mL1.4366 mL
30 mM0.0479 mL0.2394 mL0.4789 mL1.1971 mL
DMSO40 mM0.0359 mL0.1796 mL0.3591 mL0.8978 mL
50 mM0.0287 mL0.1437 mL0.2873 mL0.7183 mL
60 mM0.0239 mL0.1197 mL0.2394 mL0.5986 mL
80 mM0.0180 mL0.0898 mL0.1796 mL0.4489 mL
100 mM0.0144 mL0.0718 mL0.1437 mL0.3591 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础